کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
11030685 | 1646187 | 2018 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Familial hypercholesterolemia treatments: Guidelines and new therapies
ترجمه فارسی عنوان
درمان های فریبنده کلسترول بالا: دستورالعمل ها و درمان های جدید
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
هیپرکلسترولمی خانوادگی، گیرنده های لیپوپروتئین با چگالی پایین، داروهای کاهش دهنده چربی، دستورالعمل
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی
Familial hypercholesterolemia (FH) is a genetic disorder resulting from mutations in genes encoding proteins involved in the metabolism of low density lipoproteins (LDL) and characterized by premature cardiovascular disease due to the exposure to high levels of LDL-cholesterol (LDL-C) from birth. Thus, the early identification of FH subjects, followed by appropriate treatment is essential to prevent or at least delay the onset of cardiovascular events. However, FH is largely underdiagnosed; in addition, FH patients are frequently not adequately treated, despite the availability of several pharmacological therapies to significantly reduce LDL-C levels. Current guidelines recommend LDL-C targets for FH (either heterozygotes [HeFH] or homozygotes [HoFH]) <100â¯mg/dL (<2.6â¯mmol/L) for adults or <70â¯mg/dL (<1.8â¯mmol/L) for adults with CHD or diabetes, and <135â¯mg/dL (<3.5â¯mmol/L) for children. With the pharmacological options now available, which include statins as a first approach, ezetimibe, and the recently approved monoclonal antibodies targeting PCSK9, the guideline recommended LDL-C target levels can be achieved in the majority of heterozygous FH subjects, while for the most severe forms of homozygous FH, the addition of therapies such as lomitapide either with or without apheresis may be required.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Atherosclerosis - Volume 277, October 2018, Pages 483-492
Journal: Atherosclerosis - Volume 277, October 2018, Pages 483-492
نویسندگان
Frederick J. Raal, G. Kees Hovingh, Alberico L. Catapano,